Recombinant Human/Feline CXCL12/SDF-1 beta (aa 22-93)


There are currently no images for CXCL12/SDF-1 beta (351-FS).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Reactivity Hu, FeSpecies Glossary
Applications Bioactivity

Order Details

View Available Formulations
Catalog# & Formulation Size Price

Recombinant Human/Feline CXCL12/SDF-1 beta (aa 22-93) Summary

Details of Functionality
Measured by its ability to chemoattract 5-10 day cultured human peripheral blood lymphocytes (PBL). The ED50 for this effect is 10-30 ng/mL. Measured by its ability to chemoattract BaF3 mouse pro‑B cells transfected with human CXCR4. The ED50 for this effect is 0.3-1.5 ng/mL.
E. coli-derived CXCL12/SDF-1 beta protein
Accession #
N-terminal Sequence
Protein/Peptide Type
Recombinant Proteins
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.


Theoretical MW
8 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read Publications using
351-FS in the following applications:

Packaging, Storage & Formulations

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein.
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain
Reconstitution Instructions
Reconstitute at 50 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.


This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human/Feline CXCL12/SDF-1 beta (aa 22-93)

  • CXCL12/SDF-1 beta
  • hSDF-1beta
  • SDF 1beta
  • SDF1 beta
  • SDF1b


CXCL12, also known as SCYB12, PBSF and SDF-1 beta, is an 8.3 kDa, heparin-binding member of the CXC (or alpha-) family of chemokines (1, 2). Feline CXCL12( beta ) is synthesized as a 93 amino acid (aa) precursor that contains a 21 aa signal sequence and a 72 aa mature region (3). The mature molecule exhibits a typical three antiparallel beta -strand chemokine-like fold. There are no potential N-linked glycosylation sites. N-terminal aa’s 1-8 form a receptor binding site, while aa’s 1 and 2 (Lys-Pro) are involved in receptor activation (4). The C-terminus is likely associated with heparin binding (5). SDF-1 beta circulates and undergoes proteolytic processing. CD26 will remove the first two N-terminal amino acids, possibly creating a reduced-activity chemokine (5, 6). In addition to the beta -isoform, alternate splicing of the feline SDF-1 gene generates an alpha -isoform. The alpha isoform is identical to SDF-1 beta, but shorter by four aa’s at the C-terminus (3). Although alpha - and beta -isoforms show similar activity, SDF-1 alpha is differentially processed, and different cells secrete the two isoforms (5, 7). Mature feline SDF-1 beta is 96%, 97% and 100% aa identical to rat, mouse and human SDF-1 beta, respectively. Human (and by inference, feline) SDF-1 is active on mouse cells. SDF-1 alpha and beta are reported to be monomers at neutral pH and physiologic ionic strength (4). SDF-1 alpha is also reported to form dimers in the presence of heparansulfate (8). On the cell surface, this may well facilitate SDF-1 interaction with its two receptors, CXCR4 and syndecan-4 (9). Heparin sulfate is known to protect SDF-1 from proteolysis, and CXCR4 exists constitutively as a dimer (9-11). Among its many functions, CXCL12 is known to influence lymphopoiesis, regulate patterning and cell number of neural progenitors, and promote angiogenesis (12, 13). It also enhances the survival of myeloid progenitor cells.

  1. Zlotnik, A. and O. Yoshie (2000) Immunity 12:121.
  2. Rollins, B.J. (1997) Blood 90:909.
  3. Nishimura, Y. et al. (1998) Eur. J. Immunogenet. 25:303.
  4. Crump, M.P. et al. (1997) EMBO J. 16:6996.
  5. Sierra, M.D. L. et al. (2004) Blood 103:2452.
  6. Davis, D.A. et al. (2005) Blood 105:4561.
  7. Stumm, R.K. et al. (2002) J. Neurosci. 22:5865.
  8. Veldkamp, C.T. et al. (2005) Protein Sci. 14:1071.
  9. Charnaux, N. et al. (2005) FEBS J. 272:1937.
  10. Percherancier, Y. et al. (2005) J. Biol. Chem. 280:9895.
  11. Babcock, G.J. et al. (2003) J. Biol. Chem. 278:3378.
  12. Klein, R.S. et al. (2004) Trends Immunol. 25:306.
  13. Salcedo, R. and J.J. Oppenheim (2003) Microcirculation 10:359.
  14. Broxmeyer, H.E. et al. (2003) J. Leukoc. Biol. 73:630.

Customers Who Viewed This Item Also Viewed...

Species: Hu
Applications: Flow, IHC, CyTOF-ready, Neut
Species: Hu, Mu, Rt, Pm
Applications: WB, ELISA, Flow, ICC/IF, IHC, IHC-P
Species: Mu, Rt
Applications: WB, ELISA, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP
Species: Mu, Rt
Species: Hu, Mu, Rt, Ca, Pm
Applications: WB, IHC, IHC-P, IP
Species: Hu, Mu, Rt, Rb
Applications: WB, IHC, IHC-P
Species: Hu
Applications: Flow, CyTOF-ready, ICC, Neut
Species: Hu, Mu, Rt, Ca, Rb
Applications: WB, Simple Western, Flow, ICC/IF, IHC, IHC-Fr, IHC-P
Species: Hu
Applications: Flow, IHC, CyTOF-ready
Species: Hu
Applications: WB, Simple Western, CyTOF-ready, ELISA(Cap), ELISA(Det), ICC, ICFlow, Neut, ELISA(Sta)
Species: Mu
Applications: WB, IHC, Neut
Species: Hu
Applications: WB, Simple Western, IHC, ICC
Species: Hu, Mu
Applications: WB, IHC, IHC-P
Species: Mu

Publications for CXCL12/SDF-1 beta (351-FS)(7)

We have publications tested in 4 confirmed species: Human, Mouse, Chicken, N/A.

We have publications tested in 3 applications: Bioassay, ELISA (Standard), In Vivo.

Filter By Application
ELISA (Standard)
In Vivo
All Applications
Filter By Species
All Species
Showing Publications 1 - 7 of 7.
Publications using 351-FS Applications Species
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012;487(7408):505-9. 2012 [PMID: 22763448] (Bioassay, Human) Bioassay Human
Wei L, Kanbe K, Lee M, Wei X, Pei M, Sun X, Terek R, Chen Q Stimulation of chondrocyte hypertrophy by chemokine stromal cell-derived factor 1 in the chondro-osseous junction during endochondral bone formation. Dev. Biol., 2010;341(1):236-45. 2010 [PMID: 20206617] (Bioassay, Chicken) Bioassay Chicken
Biancotto A, Iglehart SJ, Lisco A, Vanpouille C, Grivel JC, Lurain NS, Reichelderfer PS, Margolis LB Upregulation of human cytomegalovirus by HIV type 1 in human lymphoid tissue ex vivo. AIDS Res. Hum. Retroviruses, 2008;24(3):453-62. 2008 [PMID: 18327985] (ELISA (Standard), N/A) ELISA (Standard) N/A
Biancotto A, Grivel JC, Iglehart SJ, Vanpouille C, Lisco A, Sieg SF, Debernardo R, Garate K, Rodriguez B, Margolis LB, Lederman MM Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood, 2007;109(10):4272-9. 2007 [PMID: 17289812] (ELISA (Standard), N/A) ELISA (Standard) N/A
Ohab JJ, Fleming S, Blesch A, Carmichael ST A neurovascular niche for neurogenesis after stroke. J. Neurosci., 2006;26(50):13007-16. 2006 [PMID: 17167090] (In Vivo, Mouse) In Vivo Mouse
Muller A, Sonkoly E, Eulert C, Gerber PA, Kubitza R, Schirlau K, Franken-Kunkel P, Poremba C, Snyderman C, Klotz LO, Ruzicka T, Bier H, Zlotnik A, Whiteside TL, Homey B, Hoffmann TK Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Int. J. Cancer, 2006;118(9):2147-57. 2006 [PMID: 16331601] (Bioassay, Human) Bioassay Human
de Lavareille A, Roufosse F, Schandene L, Stordeur P, Cogan E, Goldman M Clonal Th2 cells associated with chronic hypereosinophilia: TARC-induced CCR4 down-regulation in vivo. Eur. J. Immunol., 2001;31(4):1037-46. 2001 [PMID: 11298328] (Bioassay, Human) Bioassay Human

Reviews for CXCL12/SDF-1 beta (351-FS) (0)

There are no reviews for CXCL12/SDF-1 beta (351-FS). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for CXCL12/SDF-1 beta (351-FS) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Other Available Formats

Additional CXCL12/SDF-1 beta Products

Bioinformatics Tool for CXCL12/SDF-1 beta (351-FS)

Discover related pathways, diseases and genes to CXCL12/SDF-1 beta (351-FS). Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
Visit Tool

Diseases for CXCL12/SDF-1 beta (351-FS)

Discover more about diseases related to CXCL12/SDF-1 beta (351-FS).

Pathways for CXCL12/SDF-1 beta (351-FS)

View related products by pathway.

PTMs for CXCL12/SDF-1 beta (351-FS)

Learn more about PTMs related to CXCL12/SDF-1 beta (351-FS).

Blogs on CXCL12/SDF-1 beta

There are no specific blogs for CXCL12/SDF-1 beta, but you can read our latest blog posts.

Customers Who Bought This Also Bought

Contact Information

Product PDFs


Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.


Review this Product

Be the first to review our Recombinant Human/Feline CXCL12/SDF-1 beta (aa 22-93) and receive a gift card or discount.


Gene Symbol CXCL12